Company profile
Bolt Biotherapeutics, Inc.
NASDAQ: BOLT · Healthcare · Biotechnology
#663 of 1,422 Healthcare companies by revenue42nd-percentile growth
EA Score
39DFH 38DQ 40GM 40SS 36
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, balance-sheet leverage · ↓ listing tenure, growth stability
Methodology →Revenue TTM
$4.7M
Rev growth YoY (TTM)
+12.8%
Net income (FY)
-$33.4M
Employees
23
as of 2026-08-23
Market cap
$7.0M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.7M$7.7M2025
Net income-$33.4M-$33.4M2025
Operating income-$36.1M-$36.1M2025
Total assets$56.7M$56.7M2025
Liabilities$30.2M$30.2M2025
Equity$26.5M$26.5M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bolt Biotherapeutics, Inc.’s revenue?
Bolt Biotherapeutics, Inc. booked $7.7M in FY2025 revenue, growing 0.1% year over year — about the middle of the pack among Healthcare companies we track, at a -433.7% net margin.
Peers · Healthcare
Aclaris Therapeutics, Inc.47DPulmatrix, Inc.46DCrinetics Pharmaceuticals, Inc.53DBeyond Air, Inc.42DAmazonas Florestal, Ltd——COSCIENS Biopharma Inc.43DNeighbors
San Mateo →Key facts
CEOWilliam Quinn
SectorHealthcare
IndustryBiotechnology
HeadquartersRedwood City, CA
ExchangeNASDAQ: BOLT
Employees23
IPO date2021-02-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.